[1]李红磊,谢亚玎,伍 杰,等.胆管癌患者血清circRNA MBOAT2，circRNA ACTN4水平表达与临床病理特征及预后的关系研究[J].现代检验医学杂志,2025,40(05):35-39.[doi:10.3969/j.issn.1671-7414.2025.05.007]
　LI Honglei,XIE Yading,WU Jie,et al.Study on the Relationship between the Expression of Serum circRNA MBOAT2 and circRNA ACTN4 Levels and Clinicopathological Features and Prognosis in Patients with Cholangiocarcinoma[J].Journal of Modern Laboratory Medicine,2025,40(05):35-39.[doi:10.3969/j.issn.1671-7414.2025.05.007]
点击复制

胆管癌患者血清circRNA MBOAT2，circRNA ACTN4水平表达与临床病理特征及预后的关系研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年05期
页码:
35-39
栏目:
论著
出版日期:
2025-09-15

文章信息/Info

Title:
Study on the Relationship between the Expression of Serum circRNA MBOAT2 and circRNA ACTN4 Levels and Clinicopathological Features and Prognosis in Patients with Cholangiocarcinoma
文章编号:
1671-7414（2025）05-035-05
作者:
李红磊1a，谢亚玎1a，伍 杰1a，谭 诚1b，张会娟2
1．邯郸市第一医院 a.肝胆外二科；b.临床技能培训中心，河北邯郸 056000；2．邯郸市传染病医院外科，河北邯郸 056000
Author(s):
LI Honglei1a，XIE Yading1a，WU Jie1a，TAN Cheng1b，ZHANG Huijuan2
1a. Department of Hepatobiliary Surgery; 1b. Clinical Skills Training Center，the First Hospital of Handan City，Hebei Handan 056000，China；2. Department of Infectious，Disease Hospital in Handan City, Hebei Handan 056000
关键词:
胆管癌; 环状RNA膜结合O-酰基转移酶2; 环状RNA辅肌动蛋白α4; 诊断价值; 病理特征
分类号:
R735.8；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.05.007
文献标志码:
A
摘要:
目的探究胆管癌患者血清环状RNA膜结合O-酰基转移酶2（circRNAMBOAT2）和环状RNA辅肌动蛋白α4（circRNAACTN4）的表达变化及其与预后的关系。方法选择2021年1月～2024年1月在邯郸市第一医院诊治的96例胆管癌患者作为胆管癌组，另选85例胆管内结石患者和90例健康志愿者分别作为结石组和对照组。定量实时反转录聚合酶链式反应（qRT-PCR）检测血清circRNAMBOAT2，circRNAACTN4水平，分析circRNAMBOAT2，circRNAACTN4与临床病理特征的关系；Pearson分析胆管癌患者circRNAMBOAT2，circRNAACTN4的相关性；ROC分析circRNAMBOAT2，circRNAACTN4对胆管癌发生的诊断价值；COX分析胆管癌患者预后不良的影响因素；Kaplan-Meier生存曲线法进行生存分析。结果胆管癌组血清circRNAMBOAT2（1.24±0.38），circRNAACTN4（1.27±0.42）高于结石组（1.02±0.31，1.05±0.34）和对照组（0.83±0.24，0.78±0.21），结石组高于对照组，差异具有统计学意义（t=5.016～14.025，均P<0.05）。胆管癌组患者circRNAMBOAT2与circRNAACTN4呈正相关（r=0.428，P<0.05）；circRNAMBOAT2，circRNAACTN4联合诊断胆管癌发生优于单独诊断（Z=4.063，4.004，均P<0.05）；circRNAMBOAT2，circRNAACTN4与临床分期、淋巴结状态相关（t=5.091～5.984，均P<0.05）；淋巴结状态阳性、circRNAMBOAT2，circRNAACTN4升高为患者死亡的独立危险因素（HR=1.527，1.582，1.727，均P<0.05）。高表达circRNAMBOAT2（23.40%），circRNAACTN4（24.00%）的患者累积生存率均低于低表达（46.94%，47.83%）患者，差异具有统计学意义（χ2=5.809，5.946，均P<0.05）。结论circRNAMBOAT2，circRNAACTN4水平随着疾病进展升高，联合检测对诊断胆管癌发生具有一定价值，是患者死亡的独立危险因素。
Abstract:
Objective To investigate the expression changes of serum circRNA membrane bound O-acyltransferase 2 (circRNA MBOAT2) and circRNA recombinant actinin 4 (circRNA ACTN4) in patients with cholangiocarcinoma and their relationship with prognosis. Methods 96 patients with cholangiocarcinoma treated at the First Hospital of Handan City from January 2020 to January 2022 in Department of Hepatobiliary Surgery were regarded as as the cholangiocarcinoma group. Additionally, 85 patients with intraductal stones and 90 healthy volunteers were collected as the stone group and control group, respectively. Quantitative real-time reverse transcription PCR（qRT-PCR）was applied to detect the expression levels of circRNA MBOAT2 and circRNA ACTN4. χ2 test was applied to analyze the relationship between circRNA MBOAT2 and circRNA ACTN4 and clinical pathological features. Pearson was applied to analyze the correlation between circRNA MBOAT2 and circRNA ACTN4 in patients with cholangiocarcinoma. ROC was applied to analyze the diagnostic value of circRNA MBOAT2 and circRNA ACTN4 in the occurrence of cholangiocarcinoma. COX was applied to analyze the influencing factors of poor prognosis in patients with cholangiocarcinoma. Kaplan-Meier method was applied for survival analysis. Results circRNA MBOAT2（1.24±0.38）and circRNA ACTN4（1.27±0.42） in cholangiocarcinoma group were higher than those in stone group（1.02±0.31，1.05±0.34）and control group（0.83±0.24，0.78±0.21）, and the stone group was higher than that in control group, with statistically significance(t=5.016～14.025, all P<0.05). There was a positive correlation between circRNA MBOAT2 and circRNA ACTN4 in patients with cholangiocarcinoma group (r=0.428, P<0.05). Combined diagnosis of MBOAT2 and ACTN4 was better than single diagnosis of cholangiocarcinoma (Z=4.063, 4.004, all P<0.05); circRNA MBOAT2 and circRNA ACTN4 were correlated with clinical staging and lymph node status (t=5.091～5.984, all P<0.05). Positive lymph node status and elevated levels of circRNA MBOAT2 and circRNA ACTN4 were independent risk factors for mortality (HR=1.527, 1.582, 1.727, all P<0.05). The cumulative survival rate of patients with high expression of circRNA MBOAT2(23.40% vs 46.94%) and circRNA ACTN4(24.00% vs 47.83%) was lower than that of patients with low expression (χ2=5.809，5.946，all P<0.05). Conclusion The serum levels of circRNA MBOAT2 and circRNA ACTN4 increase with the progression of the disease, and the combination of the two has certain value in diagnosing the occurrence of cholangiocarcinoma.

参考文献/References:

[1] BANALES J M, MARIN J J G, LAMARCA A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nature Reviews Gastroenterology & Hepatology, 2020, 17(9): 557-588.
[2] 薛栋,邬君义,贺晓宇,等.KIF14在肝内胆管癌中的表达及对胆管癌细胞增殖和侵袭能力的影响[J].现代肿瘤医学,2023,31(14):2678-2682. XUE D, WU J Y, HE X Y, et al. Expression of KIF14 in intrahepatic cholangiocarcinoma and its effects on proliferation and invasion of cholangiocarcinoma cells[J]. Journal of Modern Oncology, 2023, 31(14): 2678-2682.
[3] XU S, LEI S L, LIU K J, et al. CircSFMBT1 promotes pancreatic cancer growth and metastasis via targeting miR-330-5p/PAK1 axis[J]. Cancer Gene Therapy, 2021, 28(3): 234-249.
[4] ZHOU X X, LIU K, CUI J, et al. Circ-MBOAT2 knockdown represses tumor progression and glutamine catabolism by miR-433-3p/GOT1 axis in pancreatic cancer[J]. Journal of Experimental & Clinical Cancer Research, 2021, 40(1): 124.
[5] LIANG X J, LIU X, SONG Z H, et al. Hsa_circ_0097922 promotes tamoxifen resistance and cell malignant behaviour of breast cancer cells by regulating ACTN4 expression via miR-876-3p[J]. Clinical and Experimental Pharmacology and Physiology, 2022, 49(12): 1257-1269.
[6] CADAMURO M, STRAZZABOSCO M. Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention[J]. Advances in Cancer Research, 2022, 156(32): 39-53.
[7] 王希方,郑伟,马东瑞,等.ALKBH5调控GEFT的m6A修饰对胆管癌转移及EMT的实验研究[J].现代检验医学杂志,2023,38(4):1-7, 21. WANG X F, ZHENG W, MA D R, et al. Experimental study of GEFT m6A modification regulated by ALKBH5 on cholangiocarcinoma metastasis and EMT[J]. Journal of Modern Laboratory Medicine, 2023, 38(4): 1-7, 21.
[8] ZHA Z B，CHEN L，ZHENG Z，et al. Circular RNA_HIPK3-targeting miR-93-5p regulates KLF9 expression level to control acute kidney injury [J]. Computational and Mathematical Methods in Medicine，2023，2023：1318817.
[9] LI W Z, LIU J Q, CHEN M, et al. Circular RNA in cancer development and immune regulation[J]. Journal of Cellular and Molecular Medicine, 2022, 26(6): 1785-1798.
[10] 高圣钰,刘爽,魏微微,等.circRNA影响NSCLC增殖、侵袭相关信号通路研究进展[J].中国老年学杂志,2023,43(5):1264-1267. GAO S Y, LIU S, WEI W W, et al．Research progress on the impact of circRNA on NSCLC proliferation and invasion related signaling pathways [J]. Chinese Journal of Gerontology, 2023, 43(5): 1264-1267.
[11] YU X P, TONG H J, CHEN J L, et al. CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma progression and lipid metabolism reprogramming by stabilizing PTBP1 to facilitate FASN mRNA cytoplasmic export[J]. Cell Death & Disease, 2023, 14(1): 20.
[12] TANG X L, SUN G R, HE Q S, et al. Circular noncoding RNA circMBOAT2 is a novel tumor marker and regulates proliferation/migration by sponging miR-519d-3p in colorectal cancer[J]. Cell Death & Disease, 2020, 11(8): 625.
[13] TENTLER D, LOMERT E, NOVITSKAYA K, et al. Role of ACTN4 in tumorigenesis, metastasis, and EMT[J]. Cells, 2019, 8(11): 1427.
[14] 李顺乐,徐蒙,李蓉,等.肝内胆管癌组织中circACTN4 mRNA和THBS1mRNA的表达与临床病理特征及预后的关系研究[J].现代检验医学杂志,2024,39(3):1-7. LI S L, XU M, LI R, et al. Relationship between the expression of circACTN4 mRNA and THBS1 mRNA in intrahepatic cholangiocarcinoma tissue with clinicopathological features and prognosis[J]. Journal of Modern Laboratory Medicine, 2024, 39(3): 1-7.
[15] WANG X S, XING L, YANG R, et al. The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC[J]. Molecular Cancer, 2021, 20(1): 91.

相似文献/References:

[1]肖小平,郭 玲,张 熊.胆管癌组织LOXL2 mRNA与Tenascinm-C mRNA表达的临床应用研究[J].现代检验医学杂志,2017,32(03):79.[doi:10.3969/j.issn.1671-7414.2017.03.021]
　XIAO Xiao-ping,GUO Ling,ZHANG Xiong.Clinical Application of the Expression of LOXL2 mRNA and Tenascin-C mRNA in Tissues of the Bile Duct Cancer[J].Journal of Modern Laboratory Medicine,2017,32(05):79.[doi:10.3969/j.issn.1671-7414.2017.03.021]
[2]遆振宇,高小鹏,千东维,等.血清 sPDL1水平和外周血 NLR在判断晚期胆管癌患者生存预后中的意义[J].现代检验医学杂志,2019,34(06):41.[doi:10.3969 ／ j.issn.1671-7414.2019.06.010]
　TI Zhen-yu,GAO Xiao-peng,QIAN Dong-wei,et al.Soluble Programmed Death-Ligand 1 (sPDL1) and Neutrophilto-Lymphocyte Ratio (NLR) Predicts Prognostic Survival in Advanced Biliary Tract Cancer Patients Treated with Palliative Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(05):41.[doi:10.3969 ／ j.issn.1671-7414.2019.06.010]
[3]王希方,郑 伟,马东瑞,等.ALKBH5 调控GEFT 的m6A 修饰对胆管癌转移及EMT 的实验研究[J].现代检验医学杂志,2023,38(04):1.[doi:10.3969/j.issn.1671-7414.2023.04.001]
　WANG Xifang,ZHENG Wei,MA Dongrui,et al.Experimental Study of GEFT m6A Modification Regulated by ALKBH5 on Cholangiocarcinoma Metastasis and EMT[J].Journal of Modern Laboratory Medicine,2023,38(05):1.[doi:10.3969/j.issn.1671-7414.2023.04.001]

备注/Memo

备注/Memo:
基金项目：2022年度河北省医学科学研究课题计划（编号：20220483）。
作者简介：李红磊（1987-），男，本科，主治医师，从事胆管癌患者临床术后预测模型及相关肿瘤标志物研究，E-mail：a25wdl@163.com。
通讯作者：谢亚玎（1989-），女，硕士研究生，主治医师，研究方向：肝胆外科，E-mail：f95acb@163.com。
更新日期/Last Update: 2025-09-15